Therapeutic effect of human umbilical cord mesenchymal stem cells transplantation in the treatment of chronic liver failure

doi:10.3969/j.issn.2095-4344.2017.13.015

Abstract

Abstract:

BACKGROUND: Umbilical cord mesenchymal stem cells are plentifully and conveniently obtained with a high proliferative ability, and have opened up a new way to treat patients with liver failure as they can differentiate into hepatocyte-like cells.
OBJECTIVE: To observe the safety and efficacy in the treatment of chronic liver failure by transplanting umbilical cord mesenchymal stem cells.
METHODS: Using parallel contrast method, 50 patients with chronic liver failure were divided into two groups, namely a stem cell group and a control group, containing 25 patients in each group. For the first group, transplantation of umbilical cord mesenchymal stem cells, (1.4-2.3)×10⁶/kg, 100 mL, was given on the basis of medical comprehensive treatment, while for the second group only simple medical comprehensive treatment was given. The injection was done every 15 days, totally three times. Liver functions, prothrombin activity, Model for End-Stage Liver Disease (MELD) score, clinical symptoms, survival and side effects of the patients were observed before and 2, 4, 12 and 24 weeks after the treatment.
RESULTS AND CONCLUSION: Compared with the control group, the albumin level and prothrombin activity were significantly increased in the stem cell group 12 and 24 weeks after treatment (P < 0.05), while the MELD score was significantly decreased in the stem cell group at 4, 12 and 24 weeks after treatment (P < 0.05). There was no significant difference in alanine aminotransferase and total bilirubin levels between the two groups (P > 0.05). Four weeks after treatment, clinical symptoms of the stem cell group improved significantly in comparison with the control group (P < 0.05). During the 24-week follow-up, the survival rate in the stem cell group was significantly higher than that in the control group (P < 0.05). Additionally, there were no adverse reactions and liver cancer associated with the stem cell therapy. Results show that it is safe and effective to treat patients with chronic liver failure through the transplantation of umbilical cord mesenchymal stem cells, and the cell transplantation can significantly improve patients’ survival rate.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

Key words: Umbilical Cord, Mesenchymal Stem Cell Transplantation, Liver Failure, Hepatitis B virus, Tissue Engineering

CLC Number:

R394.2

Zhang Sui, Liu Li-ping, Ma Wen-bo, Jia Bei, Wang Hai-fang, Xie Cong-jun. Therapeutic effect of human umbilical cord mesenchymal stem cells transplantation in the treatment of chronic liver failure[J]. Chinese Journal of Tissue Engineering Research, 2017, 21(13): 2056-2061.

Figures/Tables 2

References

[1] 中华医学会感染病学分会肝衰竭与人工肝学组. 肝衰竭诊治指南(2012年版)[J].实用器官移植电子杂志,2013,1(4):193- 202.

[2] Xue HL, Zeng WZ, Wu XL, et al. Clinical therapeutic effects of human umbilical cord-derived mesenchymal stem cells transplantation in the treatment of end-stage liver disease. Transplant Proc. 2015;47(2):412-418.

[3] Shin TH, Kim HS, Choi SW, et al. Mesenchymal Stem Cell Therapy for Inflammatory Skin Diseases: Clinical Potential and Mode of Action. Int J Mol Sci. 2017;18(2): E244.

[4] Wang Z, Wang L, Su X, et al. Rational transplant timing and dose of mesenchymal stromal cells in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Stem Cell Res Ther. 2017;8(1):21.

[5] Kanelidis A, Premer C, Lopez JG, et al. Route of Delivery Modulates the Efficacy of Mesenchymal Stem Cell Therapy for Myocardial Infarction: A Meta-Analysis of Preclinical Studies and Clinical Trials.Circ Res. 2016: CIRCRESAHA. 116.309819.

[6] Vickers ER, Karsten E, Flood J, et al. A preliminary report on stem cell therapy for neuropathic pain in humans. J Pain Res. 2014;7:255-263.

[7] Ma XR, Tang YL, Xuan M, et al. Transplantation of autologous mesenchymal stem cells for end-stage liver cirrhosis: a meta-analysis based on seven controlled trials. Gastroenterol Res Pract. 2015;2015:908275.

[8] Peng L, Xie DY, Lin BL, et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology. 2011 Sep 2;54(3):820-828.

[9] 曲乃方,王者令,闫兆平,等. 38例慢性肝衰竭患者经干细胞治疗48周效果观察[J]. 中华细胞与干细胞杂志:电子版,2013,3(2): 73-77.

[10] 姚豫桐,罗兰云,薛华,等. 自体外周血CD33+干细胞移植治疗晚期肝硬化100例的临床疗效分析[J].中华肝脏病杂志, 2014, 22(9):667-670.

[11] 王全楚,张凌云,王东琳. 人脐带血间充质干细胞输注治疗慢性肝衰竭患者的近期疗效观察[J].胃肠病学和肝病学杂志, 2013, 22(1):22-24.

[12] Kantarc?o?lu M, Demirci H, Avcu F, et al. Efficacy of autologous mesenchymal stem cell transplantation in patients with liver cirrhosis. Turk J Gastroenterol. 2015;26(3):244-250.

[13] Deng Q, Cai T, Zhang S, et al. Autologous Peripheral Blood Stem Cell Transplantation Improves Portal Hemodynamics in Patients with Hepatitis B Virus-related Decompensated Cirrhosis. Hepat Mon. 2015;15(12):e32498.

[14] Yu SJ, Chen LM, Lyu S, et al. Safety and efficacy of human umbilical cord derived-mesenchymal stem cell transplantation for treating patients with HBV-related decompensated cirrhosis. Zhonghua Gan Zang Bing Za Zhi. 2016;24(1):51-55.

[15] 佟立新,张岁,闫宝勇,等. 人脐带间充质干细胞经外周静脉移植治疗失代偿期肝硬化的临床疗效[J]. 世界华人消化杂志, 2015, 23(15):2457-2462.

[16] 曾芝雨,李东良,方坚,等. 脐带间充质干细胞联合骨髓干细胞移植治疗失代偿期肝硬化：1年随访对照[J]. 中国组织工程研究, 2015,19(10): 1533-1538.

[17] 李元元, 徐若男, 施明, 等. 人脐带间充质干细胞治疗慢加急性肝衰竭患者的初步临床观察[J]. 中华细胞与干细胞杂志:电子版, 2015, 5(1):36-40.

[18] 刘波,董静,张骏飞,等.人脐带间充质干细胞治疗慢加急性肝衰竭患者近期疗效与安全性分析[J]. 实用肝脏病杂志, 2013, 16(1): 29-31.

[19] Karahuseyinoglu S, Cinar O, Kilic E, et al. Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cells. 2007;25(2):319-331.

[20] Zhou C, Yang B, Tian Y, et al. Immunomodulatory effect of human umbilical cord Wharton's jelly-derived mesenchymal stem cells on lymphocytes. Cell Immunol. 2011;272(1):33-38.

[21] Feng T, Zhang J, Zeng G, et al. Therapeutic potential of umbilical cord mesenchymal stem cells in mice with acute hepatic failure. Int J Artif Organs. 2015;38(5):271-276.

[22] Yang JF, Cao HC, Pan QL, et al. Mesenchymal stem cells from the human umbilical cord ameliorate fulminant hepatic failure and increase survival in mice. Hepatobiliary Pancreat Dis Int. 2015;14(2):186-193.

[23] Shi M, Zhang Z, Xu R, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med. 2012;1(10):725-731.

[24] Liu WH, Song FQ, Ren LN, et al. The multiple functional roles of mesenchymal stem cells in participating in treating liver diseases. J Cell Mol Med. 2015;19(3):511-520.

[25] Yovchev MI, Xue Y, Shafritz DA, et al. Repopulation of the fibrotic/cirrhotic rat liver by transplanted hepatic stem/progenitor cells and mature hepatocytes. Hepatology. 2014;59(1):284-295.

[26] Herrera MB, Fonsato V, Bruno S, et al. Human liver stem cells improve liver injury in a model of fulminant liver failure. Hepatology. 2013;57(1):311-319.

[27] Chai NL, Zhang XB, Chen SW, et al. Umbilical cord-derived mesenchymal stem cells alleviate liver fibrosis in rats. World J Gastroenterol. 2016;22(26):6036-6048.

[28] Li T, Yan Y, Wang B, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev. 2013;22(6):845-854.

[29] Eom YW, Shim KY, Baik SK. Mesenchymal stem cell therapy for liver fibrosis. Korean J Intern Med. 2015;30(5):580-589.

[30] Hirata M, Ishigami M, Matsushita Y, et al. Multifaceted Therapeutic Benefits of Factors Derived From Dental Pulp Stem Cells for Mouse Liver Fibrosis. Stem Cells Transl Med. 2016;5(10):1416-1424.

[31] Meier RP, Mahou R, Morel P, et al. Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice. J Hepatol. 2015;62(3):634-641.

[32] Li Q, Zhou X, Shi Y, et al. In vivo tracking and comparison of the therapeutic effects of MSCs and HSCs for liver injury. PLoS One. 2013;8(4):e62363.

[33] Li T, Zhu J, Ma K, et al. Autologous bone marrow-derived mesenchymal stem cell transplantation promotes liver regeneration after portal vein embolization in cirrhotic rats. J Surg Res. 2013;184(2):1161-1173.

[34] Xue G, Han X, Ma X, et al. Effect of Microenvironment on Differentiation of Human Umbilical Cord Mesenchymal Stem Cells into Hepatocytes In Vitro and In Vivo. Biomed Res Int. 2016;2016:8916534.

[35] Al Ghrbawy NM, Afify RA, Dyaa N, et al. Differentiation of Bone Marrow: Derived Mesenchymal Stem Cells into Hepatocyte-like Cells. Indian J Hematol Blood Transfus. 2016;32(3):276-283.

[36] Yang L, Wang Y, Wang X, et al. Effect of allogeneic umbilical cord mesenchymal stem cell transplantation in a rat model of hepatic cirrhosis. J Tradit Chin Med. 2015;35(1):63-68.

[37] 黄湛镰,高志良.肝衰竭的三重打击及治疗策略[J].内科急危重症杂志, 2014, 20(3):154-156.

[38] Zhang Y, Cai W, Huang Q, et al. Mesenchymal stem cells alleviate bacteria-induced liver injury in mice by inducing regulatory dendritic cells. Hepatology. 2014;59(2):671-682.

[39] Higashimoto M, Sakai Y, Takamura M, et al. Adipose tissue derived stromal stem cell therapy in murine ConA-derived hepatitis is dependent on myeloid-lineage and CD4+ T-cell suppression. Eur J Immunol. 2013;43(11):2956-2968.

[40] Sharma RR, Pollock K, Hubel A, et al. Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices.Transfusion. 2014;54(5):1418-1437.